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OBJECTIVE. Identify the relative importance of factors that impact parents’ attitudes towards 
use of their child's dried newborn blood spots for research purposes. 
METHODS. Respondents were parents aged 18 and older with at least one child aged 17 or 
younger born in Indiana visiting an urban pediatrics clinic. They were asked to rate the 
acceptability of hypothetical scenarios involving the research use of blood spots. Three pieces of 
information varied between the scenarios: 1) who would be conducting the research; 2) whether 
the child's identity would be linked to the spots; and 3) whether and how often the parents' 
consent would be sought before the research began.  
RESULTS. 506 predominantly Black and low-income parents completed the survey. The 
conjoint analysis model showed good fit (Pearson's R=0.998, p<0.001). The rank order of factors 
affecting parents’ attitudes was: 1) consent (importance score=64.9), 2) whether the child's 
identity was linked to the spot (importance score=19.4), 3) affiliation of the researcher using the 
spots (importance score=14.6). Respondents preferred being asked for their consent each time 
their children's spots would be used. They preferred that the children's identity not be linked to 
the spots and that the research is conducted by university researchers, though these issues had 
less impact on attitudes than consent. 
CONCLUSIONS. Parents strongly prefer that consent be sought for each use of their children's 




Compared to researcher affiliation and identity linkage of a child to a blood spot, consent 
protocol emerged as the strongest factor impacting Indiana parents’ attitudes about using dried 





Beginning in the 1960s, routine newborn screening began in the U.S.1,2 Since 1965, when 
it first started screening for phenylketonuria (PKU), the Indiana State Department of Health has 
collected newborn blood spots and now tests them for nearly four dozen conditions3,4. Blood 
spots are collected for each child, and the residual dried blood spots (DBS) are stored for use in 
the event that positive findings must be confirmed or that screening must be repeated5. Residual 
DBS are stored indefinitely in Indiana and may be used for quality assurance after screening, but 
are not released for research purposes6. 
 DBS are potentially useful in studies of conditions believed to be genetic or acquired in 
utero, studies of in utero environmental toxin exposure, and other research on biological 
conditions7-11. In Indiana, for example, given the state’s strong electronic medical records 
systems, e.g., the Indiana Network for Patient Care12, DBS of Indiana-born children could be 
linked with their electronic medical records to identify early markers of conditions not currently 
screened for at birth. Moreover, using DBS is feasible and potentially cost-effective compared to 
collecting fresh blood specimens10. 
 Many states in the U.S. do not explicitly regulate the use of DBS for research purposes, 
and state policies surrounding the retention and use of DBS vary greatly13. Litigation focusing on 
DBS research use in the U.S. has varied in outcome. For example, Texas now has an opt-in 
policy where parents can both disallow their child’s DBS for use in research and insist that the 
specimens be destroyed (specifically pertaining to spots collected on or after June 1, 2012)14,15.
 Researchers have long investigated attitudes towards children’s participation in a variety 
of research16-18, and, more specifically, the use of pediatric biospecimens in research19,20. Other 
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work has focused on attitudes towards using DBS in research21-25. Consistently-emerging 
concerns of respondents in previous research involving use of biomaterial include: 
anonymity/identifiability of the person whose material it is; the researcher using the 
biospecimen; and whether and how frequently parent consent is sought, among other factors21-25.  
 Policymakers have expressed a need for information concerning parental attitudes 
surrounding the research use of DBS in order to formulate acceptable policies governing their 
use26. However, little is known about the relative weight that parents place on the factors 
affecting their attitudes. Here we address the relative importance of three key factors in driving 
parental attitudes, providing needed information for the development of state policy and 
institutional research practices.  
 Our hypothesis was that parents differently weight concerns about the use of their 
children’s DBS. These concerns included: 1) whether consent is sought, 2) the affiliation of the 
researcher using the DBS, and 3) whether their children’s identity is linked to the DBS. We 
chose these factors based on existing work21-25 and hypothesized that the issue of consent was 
likely to emerge as the most significant concern.  
METHODS 
Survey Development 
 We employed conjoint analysis, a multivariate technique commonly used in marketing 
research and increasingly in health-related research, including work on attitudes about 
biobanking27. Conjoint analysis is often used to determine respondent preferences when multiple 
features or attributes impact a decision28-30. We chose a full-profile, ratings-based design. The 
survey items were generated using SPSS 17®31. 
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 A full-factorial, within-subjects, repeated measures design produces 12 scenarios (3 
levels of consent X 2 levels of identity linkage X 2 levels of who is conducting research). 
However, we were interested in conceptualizing respondents’ ratings as relative preferences, and 
the conjoint analysis approach aligns with this objective. This approach produced eight 
experimental survey items. We then strengthened the design by including four additional holdout 
items. Participants’ responses to these holdout items are used as a conjoint analysis model 
validation check. This resulted in a total of 12 orthogonal survey items. We included a 13th 
duplicate item as an index of intra-respondent reliability as has been done by other investigators 
32. 
The paper-based survey’s 13 hypothetical scenarios followed the same pattern of 
information delivery: 1) who (academicians or a pharmaceutical company) would be conducting 
the research using the DBS, 2) whether the child’s identity would be linked to his/her DBS, and 
3) whether the parent’s consent would be sought once for all research (one-time, blanket 
consent), every time the child’s DBS would be used for research, or not at all. Respondents were 
asked to rate each of the scenarios via an 11-point semantic differential scale, anchored at 
“Completely Unacceptable” (0) and “Completely Acceptable” (100). There were five different 
survey versions with the order of the 13 scenarios randomized to minimize order-effects. Figure 
1 reflects survey item wording. 
[Figure 1 about here.] 
Pilot testing of the survey with 15 English speaking adults confirmed that the survey was 
understandable and clear. The survey and research protocol were exempted from review by the 
Indiana University Institutional Review Board. 
Study Population, Recruitment, and Procedure 
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 Individuals visiting one of three urban public pediatric clinics or one private pediatric 
clinic in and around the Indianapolis metropolitan area were approached by a research assistant 
(RA) from a pediatric research network, a university research group with permission to collect 
data in clinics affiliated with the Indiana University School of Medicine. Recruitment occurred 
between June 2011 and March 2012. The IRB waived informed consent for this study. The RA 
first ensured respondent eligibility through brief screening questions. Eligibility criteria included 
English fluency, 18 years of age or older, and parent or primary caregiver to at least one child 17 
years of age or younger born in the state of Indiana. The RA then asked eligible respondents to 
keep his or her child in mind when completing the survey. For respondents with multiple 
children 17 or younger born in Indiana, the RA flipped a coin to determine whether the 
respondent should focus on the oldest or youngest child born in Indiana as the referent child 
when completing the survey.  
The RA explained the study and asked the respondents to complete a few questions, 
including ages and sexes of children, whether they recalled the referent child receiving a 
heelstick before leaving the hospital when the baby was born, and whether they had heard of 
newborn screening. The RA then provided respondents with general information about newborn 
screening (the “heelstick”) in Indiana, as well as the storage of the DBS. The RA then informed 
participants they would rate the acceptability of 13 unique scenarios, each with different 
information that described fictional (“what-if”) research situations that were not actually taking 
place, followed by some general demographic questions. The RA reiterated that the survey was 
anonymous and that the scenarios depicted in the survey were not real.  
Respondents completed surveys in 12-15 minutes, primarily while in clinic waiting 
rooms before appointments. Occasionally, respondents and their children were called back for 
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their appointments before they completed their surveys. When this occurred, respondents were 
instructed to return the survey to the RA when their appointments finished. Respondents received 
a $5 gift card for completing the survey. 
An RA scanned the completed surveys. Optical character recognition software identified 
responses, recorded them to a database, and the RA reviewed each survey’s scanned responses to 
ensure data accuracy. 
Data Analysis 
Survey responses were analyzed using conjoint analysis. Conjoint analysis produces 
importance scores, denoting which factors most strongly impact preferences/attitudes, and part-
worth utility values, denoting respondents’ preferences (here, preferences for what are acceptable 
research situations). Conjoint analysis also produces Pearson’s R and Kendall’s tau. The 
Pearson’s R coefficient is an indicator of fit between the conjoint analysis model (i.e., predicted 
responses)  and respondents’ observed (i.e., actual) responses to the eight experimental survey 
items.  The Kendall’s tau coefficient for the four holdout items was generated; this is the 
coefficient denoting how well the observed (i.e., actual) responses correlate with the predicted 
responses as produced by the holdout items. This Kendall’s tau for holdouts serves as a model 
validation index. We also report the correlation for the redundant survey items as a reliability 
check. All analyses were conducted using SPSS 17®31.  
First, we report overall importance scores for the factors, which denote the impact of each 
factor (researcher affiliation, identity linkage, and consent) upon acceptability ratings. 
Specifically, these importance scores denote the percentage of respondents’ preferences that are 




Next we examined the part-worth utility values, which sum to zero for each factor. While 
importance scores indicate how strongly a factor drives one’s preferences, part-worth utilities 
convey the preferences associated for the specific attribute levels within those factors (e.g., 
whether the respondent exhibited a preference for university researchers versus drug company 
researchers using the DBS).  
RESULTS 
 Of the 593 potential respondents approached, 521 (88%) agreed to participate. The 72 
(12% of 593) non-participants were ineligible, uninterested, or indicated they did not have time. 
Of the 521 who agreed to participate, 506 (97%) respondents completed the survey, and 15 (3%) 
either did not complete it or returned a survey to the RA with missing pages. 
 Respondents ranged in age from 18-63 with a mean age of 32 years. The referent child 
about whom the survey was completed ranged in age from newborn to 17 years of age with a 
mean age of 5.7 years. Referent children were predominantly male (51%). Respondents were 
predominantly Black or African American, not Hispanic or Latino, female, and were mother to 
the referent child. The referent child was most likely a Medicaid recipient. Other descriptive 
demographic data, including political affiliation, income, and religiosity are noted in Table 1. 
[Table 1 about here.] 
Over three-quarters of respondents (75%) indicated that they recalled their children 
receiving a heelstick when they were born. However, fewer respondents indicated that they had 
heard of newborn screening (60%).  
We first calculated overall acceptability ratings for each of the 13 scenarios. Table 2 
presents the scenarios and their overall acceptability ratings. In the scenario rated as least 
acceptable the researcher affiliation was a drug company, the child’s identity was linked to the 
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DBS, and consent was not sought (M = 28.6; SD = 36.4). In the scenario rated as most 
acceptable, the researcher affiliation was a university, the child’s identity was not linked to the 
DBS, and consent was sought for each and every use of the DBS (M = 78; SD = 29.7). Of note, 
just over 2% (12/506) of respondents found research use of DBS “completely unacceptable” 
across all scenarios, and nearly 9% (45/506) found it “completely acceptable” across all 
scenarios. We also conducted an Analysis of Variance (ANOVA) to determine whether 
demographic characteristics impacted acceptability ratings. We did not find any statistically 
significant effects of respondent race, respondent ethnicity, child and respondent sex, child and 
respondent age, or parents’ awareness of newborn screening (all Fs<3.0, all ps>.09, ns). 
[Table 2 about here.] 
 For the conjoint analysis, data for 432 out of a total of 506 respondents were usable. Of 
the unusable data (N=74), 45 respondents indicated all scenarios were acceptable, 12 respondents 
indicated all were unacceptable, 8 indicated all in the mid-range of the response scale, and 9 
failed to respond to all scenarios. Conjoint analysis requires that all survey items have responses 
and that there be some variability among the responses (to denote preferences). 
 Table 3 contains the fit indices generated by the conjoint analysis. The model showed 
strong fit with a high Pearson’s R by indicating that the predictive conjoint analysis model 
strongly fits the responses to the eight experimental survey items. The Kendall’s tau for holdouts 
also suggests that the fit between the actual ratings provided by respondents on the eight 
experimental survey items and the predicted ratings generated by the four holdout model 
validation items is very strong. The duplicated survey item showed a strong correlation of .87, 
indicating high response reliability. 
[Table 3 about here.] 
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Figure 2 presents the importance scores. Consent was the most important factor in 
respondents’ ratings of acceptability of the scenarios (average importance score of 64.9). This 
was followed by identity linkage (average importance score of 19.4), and lastly, the affiliation of 
the researcher using the DBS (average importance score of 14.6).  
[Figure 2 about here.] 
 Analyses of the part-worth utility values for each of the factors’ levels indicate that, 
focusing on the issue of consent, respondents find it unacceptable (i.e., do not prefer) when 
consent is not sought for research use of their child’s DBS (utility = -25.3). They prefer that their 
consent be sought for each and every study that would use their child’s DBS (utility = 20), 
followed by their consent being sought one time for all studies that would use their child’s DBS 
(5.3). Regarding the issue of identity linkage, respondents prefer that their child’s identity not be 
linked to his or her DBS (utility = 4.5), compared to when their child’s identity would be linked 
(utility = -4.5). Finally, respondents prefer that the research using their child’s DBS be conducted 
by university researchers (utility = 1.3), compared to researchers from a drug company (utility = 
-1.3). These part-worth utilities are presented in Figure 3. 
[Figure 3 about here.] 
DISCUSSION 
This predominantly minority, low-income study sample overwhelmingly conveyed that 
parents do not find acceptable (i.e., do not prefer) situations in which their consent would not be 
sought in order to use their children’s DBS in research. They preferred that their consent be 
sought for every use of the child’s DBS. Though not as strong an influence on attitudes, 
respondents preferred that the child’s identity not be linked to the DBS and the research be 
conducted by university researchers. Most respondents report that they recall their children 
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receiving the heelstick at birth, but over a third does not know what newborn screening is. This 
echoes calls to educate parents about newborn screening practices33.   
This work contributes to the body of literature on parent preferences concerning the 
research use of their child’s biomaterial. Specifically, this research echoes previous work 
conducted in Michigan highlighting the emphasis parents place on providing their consent to 
research use of their children’s spots21, but we have quantified the high level of importance 
parents place on consent relative to other concerns. This work also echoes public attitude 
assessments surrounding the research use of DBS, in which the opportunity to provide one’s 
permission emerges as a critical theme in both qualitative and quantitative inquiry24,25. 
Limitations and Future Directions 
 Although this study contributes to the understanding of parents’ preferences concerning 
the research use of their children’s biomaterial, several limitations should be noted. First, we 
only studied three factors that have emerged as important in previous literature (consent, identity 
linkage, and researcher affiliation), though many others may impact parents’ attitudes 
surrounding the research use of DBS21-25.  
 Another limitation is that respondents rated the acceptability of hypothetical scenarios. 
‘Real’ requests to use their children’s DBS could produce different results. It is also possible that 
respondents, especially when completing the survey in a busy, clinic setting, may not have fully 
understood the information conveyed in the 13 hypothetical scenarios. No respondents in our 
study sample, nor any of the 15 respondents to the pilot test, indicated that they had difficulty 
understanding the information being conveyed in the scenarios or the general information 
presented by the RA regarding newborn screening or blood spot storage. We used the terms 
“newborn screening” and “heelstick” to gauge participants’ awareness and recall of newborn 
14 
 
screening. Some individuals, however, might be more likely to use terms like PKU or sickle cell 
screening. Further, some respondents’ participation was interrupted by being called back for an 
appointment (N=26, 5% of 506), and there is the possibility that this could have imparted some 
response bias.   
 Although not demographically representative of Indiana parents, which are 
predominantly White34, this study sample captures individuals who could potentially be asked to 
provide consent about research use of their children’s DBS. Moreover, the importance to parents 
of providing consent for DBS research use aligns with previous findings, based on data collected 
from demographically different respondents21,25. 
 Lastly, we did not collect data specifically asking about prematurity, neonatal intensive 
care unit admissions, or other health conditions present during infancy. Presence of health 
conditions could impact the likelihood of and/or parental recall of newborn screening. 
 Future directions could build upon this work by eliciting parental preferences for the 
timing and structure of the consent process. For example, do they prefer an “opt-in” or “opt-out” 
structure? Do they prefer to be asked at the time of the screening or prior to the baby’s arrival? 
Moreover, future studies could focus on the situations in which identity linkage or consent 
waivers might be permissible, as well as parental preferences for being informed of study results 
involving their child’s DBS.  
CONCLUSIONS 
 Policymakers, those leading biobanking initiatives, and researchers using minors’ 
biomaterial in their work might benefit from taking parents’ preferences into consideration when 
developing protocols for the use of children’s biomaterial, especially consent policies. Though 
logistic problems with seeking consent for DBS research use might seem overwhelming, such 
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consent is not necessarily unattainable35. Public preferences are critically important for 
policymakers to keep in mind when developing governance policies; it is also imperative that 
policymakers understand that preferences can vary depending on the parameters of DBS use. For 
example, if the DBS are being used in research identifying treatable illnesses, perhaps parents 
would want their children’s identities linked to their specimens so that they could be notified.  
Further, democratic deliberation approaches that have been employed in biobanking-
related research36,37 and involve intensive education efforts and ongoing discourse between 
citizens and those responsible for policymaking, might render different sentiments from parents 
regarding use of their children’s biomaterial. However, many individuals from whom consent 
would be sought for DBS use would not likely be able to participate in long-term, ongoing, 
intensive education and dialogue about biomaterial use. This study’s objective was to measure 
attitudes from these individuals not undergoing a democratic deliberation process.  
Lastly, states that have already implemented governance policies on this topic, especially 
if it does not involve seeking consent from parents for use of DBS, might benefit from a re-





Figure 1. Survey item wording.  Researcher affiliation, identity linkage, and consent type were 








Figure 3. Part-worth utilities values conveying preferences for the attribute levels within each 
factor. Values below the baseline of 0 indicated non-preferred (unacceptable) attribute levels 
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Table 1: Characteristics of parent respondents and the referent child. 
  Mean Min Max 
Ages Parent Age 32 18 63 
 Referent Child Age 5.7 0 17 
Characteristic N 
% (of N 
responding) 
Parent Race (N=487) Black or African American 298 61 
 
White 169 35 
 
Other 20 4 
Parent Ethnicity (N=452) Hispanic/Latino 19 4 
 
Not Hispanic/Latino 433 96 
Referent Child’s Health Care Payer
Source (N=483) Public (Medicaid) 300 62 
 
Child Covered by Parent’s 
Policy 172 36 
 Other/Uninsured 11 2 
Parent Income Level (N=486) Less than $10,000 149 31 
 $10,000-$25,000 130 27 
 $25,000-$50,000 88 18 
 $50,000-$75,000 31 6 
 More than $75,000 88 18 
Parent Political Affiliation (N=473) Democrat 250 53 
 Independent  156 33 
 Republican 67 14 
Parent Political Views (N=468) Very Liberal 131 28 
 Moderate 221 47 
 Conservative 116 25 
Does Parent Consider Self Spiritual or 
Religious (N=494) Yes 325 66 
 No 54 11 
 Somewhat 115 23 
Respondent Relationship to Referent 
Child (N=501) Mother 419 84 
 
Father 72 14 
 














1 University N Repeated 78 29.7 
2* Drug Co. N Repeated 76.4 31.4 
3* University Y Repeated 69.4 35.1 
4 Drug Co. Y Repeated 68 35.7 
5* University N One-time 67.4 36.1 
6 Drug Co. N One-time 61.4 37.3 
7 University Y One-time 59.3 38.2 
8** University Y One-time 59 38.7 
9* Drug Co. Y One-time 57.7 38.7 
10 University N No 38.2 39.9 
11 Drug Co. N No 34.4 39.8 
12 University Y No 30.4 37.3 
13 Drug Co. Y No 28.6 36.4 
 
Scenario ratings were provided on a scale anchored at 0 (completely unacceptable) to 100 
(completely acceptable) in increments of 10. Order presentation was randomized between 
participants in five different survey versions. 
 
*Denotes that scenario was a holdout item for model validation. 





Table 3: Indices of conjoint analysis model fit. 
 Fit Index Value Significance 
Pearson’s R for Conjoint Model .998 p < .001 
Kendall’s tau for Conjoint Model .929 p = .001 
Kendall’s tau for Conjoint Model Holdouts 1.000 p = .02 
Pearson’s R for Duplicated Scenario Validation Check .874 p < .001 
 
Figure 1: Survey item wording.  Researcher affiliation, identity linkage, and consent type were 
varied across the 13 scenarios (see Table 2 for listing of variable combinations reflected in each 
scenario). 
 
Researchers at a university [drug company] would like to perform a study using the blood spots 
collected from your child when they were born.  Your child’s identity would be linked to their 
spots but would be kept private [would not be linked to their spots]. The researchers would ask 
you for your permission one time in order to use your child’s blood spots for all studies they plan 
to do [would ask you for your permission separately each and every time they wanted to use 
your child’s blood spots in a different study; would use your child’s blood spots without asking 












 Figure 3.Part-worth utilities values conveying preferences for the attribute levels within each 
factor. Values below the baseline of 0 indicated non-preferred (unacceptable) attribute levels 
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